(MedPage Today) — SAN FRANCISCO — More adults with moderate-to-severe Crohn’s disease (CD) reached clinical remission after 6 months on risankizumab (Skyrizi) versus ustekinumab (Stelara), according to a head-to-head trial.
In the phase III…
Source link : https://www.medpagetoday.com/meetingcoverage/ccc/114142
Author :
Publish date : 2025-02-08 19:03:49
Copyright for syndicated content belongs to the linked Source.
